These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7194019)

  • 1. behavior of rats and mice administered active metabolites of fluphenazine, 7-hydroxy-fluphenazine and fluphenazine-sulfoxide.
    Yamada K; Furukawa T
    Arch Int Pharmacodyn Ther; 1980 Nov; 248(1):76-85. PubMed ID: 7194019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacological studies of long-acting phenothiazines with particular reference to fluphenazine decanoate (author's transl)].
    Chen PC
    Nihon Yakurigaku Zasshi; 1978 Oct; 74(7):871-83. PubMed ID: 570538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Catalepsy produced by long-acting neuroleptics, fluphenazine enanthate and fluphenazine decanoate, in mice.
    Yamada K; Furukawa T
    Pharmacology; 1982; 24(3):147-55. PubMed ID: 7200248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of a strong influence of neuroleptic decanoates on dopaminergic and GABAergic functions.
    Ossowska K; Wolfarth S
    Pol J Pharmacol; 1995; 47(2):99-107. PubMed ID: 8688897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Behavioral and electroencephalographic effects of a depot type neuroleptic fluphenazine decanoate, in rats.
    Yamamoto T; Ueki S
    J Pharmacobiodyn; 1989 Nov; 12(11):681-92. PubMed ID: 2632765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central action of adrenaline.
    Jagiełło-Wójtowicz E
    Acta Physiol Pol; 1981; 32(2):169-80. PubMed ID: 7196677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of yohimbine on dopamine dependent behaviours in rats and mice.
    Bende MM; Bapat TR; Balsara JJ; Chandorkar AG
    Indian J Physiol Pharmacol; 1990 Jul; 34(3):195-200. PubMed ID: 2286423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of insulin hypoglycemia on central dopaminergic structures of the rat.
    Kleinrok Z; Ossowska G; Stelmasiak M; Juszkiewicz M
    Pol J Pharmacol Pharm; 1983; 35(6):489-95. PubMed ID: 6377282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Behavior of rats during one-year administration of fluphenazine and subsequent withdrawal period.
    Trzeciak HI; Herman ZS; Szkilnik R; Opiełka L; Laskawiec G; Kryk A; Kmicińska M; Stańda J; Obuchowicz E; Bień E
    Pol J Pharmacol Pharm; 1986; 38(1):9-20. PubMed ID: 3763488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antagonism of apomorphine-induced cage climbing behaviour and methamphetamine stereotypy by fenfluramine in mice.
    Gada VP; Joshi VV; Balsara JJ; Chandorkar AG
    Indian J Physiol Pharmacol; 1984; 28(4):326-30. PubMed ID: 6543532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychopharmacological profile of mesterolone.
    Baran L; Przegaliński E
    Pol J Pharmacol Pharm; 1981 Oct; 33(3):299-303. PubMed ID: 7198778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of dopamine agonists on Cebus apella monkeys with previous long-term exposure to fluphenazine.
    Lifshitz K; O'Keeffe RT; Linn GS; Lee KL; Camp-Bruno JA; Suckow RF
    Biol Psychiatry; 1997 Mar; 41(6):657-67. PubMed ID: 9066989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological studies on timiperone, a new neuroleptic drug. Part I: Behavior effects.
    Yamasaki T; Kojima H; Sakurai T; Kasahara A; Watanabe S; Fujiwara M; Ueki S
    Arzneimittelforschung; 1981; 31(4):701-7. PubMed ID: 6113833
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of central effects of noradrenaline and dopamine injected into the lateral brain ventricle in rats.
    Zebrowska-Lupina I; Malec D; Kleinrok Z
    Acta Physiol Pol; 1975; 26(3):261-74. PubMed ID: 1242288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-oxides of phenothiazine antipsychotics: effects on in vivo and in vitro estimates of dopaminergic function.
    Lewis MH; Widerlöv E; Knight DL; Kilts CD; Mailman RB
    J Pharmacol Exp Ther; 1983 Jun; 225(3):539-45. PubMed ID: 6134814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roxindole: psychopharmacological profile of a dopamine D2 autoreceptor agonist.
    Bartoszyk GD; Harting J; Minck KO
    J Pharmacol Exp Ther; 1996 Jan; 276(1):41-8. PubMed ID: 8558454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solcoseryl stimulates behavioural activity of rats.
    Braszko JJ; Winnicka MM; Wiśniewski K
    Acta Physiol Hung; 1996; 84(1):63-72. PubMed ID: 8993676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Some central effects of angiotensin II. Interactions with dopaminergic transmission.
    Georgiev V; György L; Getova D; Markovska V
    Acta Physiol Pharmacol Bulg; 1985; 11(4):19-26. PubMed ID: 3012944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Catalepsy, sedation and hypothermia induced by alpha-methyl-p-tyrosine in the rat. An ideal tool for screening of drugs active on central catecholaminergic receptors.
    Papeschi R; Randrup A
    Pharmakopsychiatr Neuropsychopharmakol; 1973 May; 6(3):137-57. PubMed ID: 4800160
    [No Abstract]   [Full Text] [Related]  

  • 20. D2 dopamine antisense RNA expression vector, unlike haloperidol, produces long-term inhibition of D2 dopamine-mediated behaviors without causing Up-regulation of D2 dopamine receptors.
    Davidkova G; Zhou LW; Morabito M; Zhang SP; Weiss B
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1187-96. PubMed ID: 9618422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.